Quest Diagnostics to Offer FDA‑Cleared Roche pTau217 Alzheimer’s Test, Expanding DGX’s Advanced Diagnostics Portfolio

Quest Diagnostics (NYSE: DGX) announced this week that it will begin offering the FDA‑cleared pTau217 blood test developed by Roche, aimed at assessing Alzheimer’s disease pathology in patients exhibiting symptoms. The test will complement the company’s existing AD‑Detect® blood panel offerings, reinforcing its position in advanced diagnostics.

The announcement was made on August 24, 2026, according to Quest Diagnostics’ official press release. The test is FDA‑cleared and designed to help assess Alzheimer’s disease pathology in symptomatic patients, joining the company’s growing portfolio of AD‑Detect® blood tests.

This development arrives shortly after the company delivered strong second‑quarter financial results on July 23, 2026, reporting revenues of $3.04 billion—up 10.2% year‑over‑year—and adjusted diluted EPS of $3.12, a 19.1% increase. In light of the results, Quest raised its full-year 2026 guidance for both revenue and EPS. These earlier results underscore the company’s growing emphasis on advanced diagnostic testing, including Alzheimer’s assays. While the addition of pTau217 does not appear to have triggered an immediate stock move in this week’s trading, it aligns with the strategic momentum reflected in the Q2 earnings.

This week’s announcement notably extends Quest’s Alzheimer’s testing capabilities. The existing AD‑Detect® offerings already include tests targeting other biomarkers; adding the FDA‑cleared pTau217 enhances Quest’s clinical utility for symptomatic patient assessment.

From an investor standpoint, while this is not a financial announcement, it represents a meaningful expansion of Quest’s advanced diagnostics platform—an area that contributed to double‑digit revenue growth in Q2. It reinforces the company’s ability to deliver innovative testing solutions at scale, consistent with its strong Q2 earnings track.

Quest Diagnostics remains well‑positioned in the healthcare diagnostics landscape, now offering an expanded Alzheimer’s test suite that includes Roche’s pTau217.

Next steps investors may watch: Any further uptake metrics for pTau217 testing among physicians or payers; commentary in the upcoming Q3 earnings call (expected October 21, 2026); and whether the addition translates into incremental organic growth in advanced diagnostics.